LORBRENA® (Lorlatinib)

Indication

LORBRENA is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) previously treated with one or more ALK tyrosine kinase inhibitors (TKIs). This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Important Safety Information and Indication

LORBRENA may cause serious side effects, including:

Liver problems due to interactions with other medicines. It is important to know what medicines should not be taken with LORBRENA.

Problems with brain (central nervous system [CNS]) function. Many patients experience problems with brain function, including problems with thinking (such as forgetfulness or confusion), mood (such as depression), speech, seeing or hearing things that are not real (hallucinations), and seizures during treatment with LORBRENA. If these problems are severe, your healthcare provider may need to have you stop taking LORBRENA.

Increases in the cholesterol and triglycerides (lipid) levels in your blood. Most patients will have an increase in the lipid levels in their blood during treatment with LORBRENA.

If you have increases in the lipid levels in your blood during treatment with LORBRENA, your healthcare provider may need to start you on a medicine to lower the levels. If you are already taking a medicine to lower the lipid levels in your blood, your healthcare provider may need to increase your dose of that medicine.
Your healthcare provider should do blood tests to check the lipid levels in your blood before starting treatment, 1 to 2 months after starting treatment, and during treatment with LORBRENA.

Heart problems. LORBRENA may cause very slow or abnormal heartbeats. Your healthcare provider should check your heart rhythm (electrocardiogram [EKG]) before starting and during treatment with LORBRENA. Tell your healthcare provider right away if you feel dizzy or faint or have abnormal heartbeats. If these problems are severe, your healthcare provider may need to have you stop taking LORBRENA or have a pacemaker placed.

Lung problems. LORBRENA may cause severe or life-threatening swelling (inflammation) of the lungs during treatment that can lead to death. Symptoms may be similar to those from lung cancer. Tell your healthcare provider right away if you have any new or worsening symptoms of lung problems, including trouble breathing, shortness of breath, cough, or fever.

If these problems are severe, your healthcare provider may need to have you stop taking LORBRENA.

Do not take LORBRENA if you take certain other medicines called strong CYP3A inducers. Ask your healthcare provider for a list of these medicines if you are not sure.

Before taking LORBRENA, tell your healthcare provider about all of your medical conditions, including if you:

are taking other medications
have had episodes of depression or seizures
have high levels of cholesterol or triglycerides in your blood
have problems with your heartbeat
have lung or breathing problems
are pregnant or plan to become pregnant. LORBRENA can harm your unborn baby.
- Your healthcare provider will do a pregnancy test before you start treatment with LORBRENA.
- Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with LORBRENA.
  - Females who are able to become pregnant should use effective non hormonal birth control during treatment with LORBRENA and for at least 6 months after the final dose of LORBRENA. Birth control pills (oral contraceptives) and other hormonal forms of birth control may not be effective if used during treatment with LORBRENA. Talk to your healthcare provider about birth control choices that are right for you during this time.
  - Males who have female partners who are able to become pregnant should use effective birth control during treatment with LORBRENA and for at least 3 months after the final dose of LORBRENA.
are breastfeeding or plan to breastfeed. It is not known if LORBRENA passes into your breast milk. Do not breastfeed during treatment with LORBRENA and for 7 days after the final dose. Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.

Do not take LORBRENA if you take certain other medicines called strong CYP3A inducers. Ask your healthcare provider for a list of these medicines if you are not sure.

The most common side effects of LORBRENA include:

swelling in your arms, legs, hands, and feet (edema)
numbness and tingling feeling in your joints or arms and legs (peripheral neuropathy)
difficulty thinking or confusion
difficulty breathing
tiredness (fatigue)
weight gain
pain in your joints
changes in mood, feeling sad or anxious
diarrhea

LORBRENA may cause decreased fertility in males. In males, this could affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.

These are not all of the possible side effects of LORBRENA. For more information, ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Indication

LORBRENA is a prescription medicine that is used to treat people with non-small cell lung cancer (NSCLC)

that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene, and
that has spread to other parts of the body, and
who have taken the medicine:
- alectinib, or ceritinib, or
- both crizotinib and at least 1 other medicine to treat NSCLC that is caused by the ALK gene, and
that is no longer responding to these treatments.

It is not known if LORBRENA is safe and effective in children.

The effectiveness of LORBRENA is based on a study that measured tumor response rate and duration of response. There is an ongoing study to find out how LORBRENA works over a longer period of time.

Please see Full Prescribing Information and Patient Information.

Scroll for Important Safety Information and indication

Important Safety Information and Indication

LORBRENA may cause serious side effects, including:

Liver problems due to interactions with other medicines. It is important to know what medicines should not be taken with LORBRENA.

Increases in the cholesterol and triglycerides (lipid) levels in your blood. Most patients will have an increase in the lipid levels in their blood during treatment with LORBRENA.

If you have increases in the lipid levels in your blood during treatment with LORBRENA, your healthcare provider may need to start you on a medicine to lower the levels. If you are already taking a medicine to lower the lipid levels in your blood, your healthcare provider may need to increase your dose of that medicine.
Your healthcare provider should do blood tests to check the lipid levels in your blood before starting treatment, 1 to 2 months after starting treatment, and during treatment with LORBRENA.

If these problems are severe, your healthcare provider may need to have you stop taking LORBRENA.

Do not take LORBRENA if you take certain other medicines called strong CYP3A inducers. Ask your healthcare provider for a list of these medicines if you are not sure.

Before taking LORBRENA, tell your healthcare provider about all of your medical conditions, including if you:

are taking other medications
have had episodes of depression or seizures
have high levels of cholesterol or triglycerides in your blood
have problems with your heartbeat
have lung or breathing problems
are pregnant or plan to become pregnant. LORBRENA can harm your unborn baby.
- Your healthcare provider will do a pregnancy test before you start treatment with LORBRENA.
- Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with LORBRENA.
  - Females who are able to become pregnant should use effective non hormonal birth control during treatment with LORBRENA and for at least 6 months after the final dose of LORBRENA. Birth control pills (oral contraceptives) and other hormonal forms of birth control may not be effective if used during treatment with LORBRENA. Talk to your healthcare provider about birth control choices that are right for you during this time.
  - Males who have female partners who are able to become pregnant should use effective birth control during treatment with LORBRENA and for at least 3 months after the final dose of LORBRENA.
are breastfeeding or plan to breastfeed. It is not known if LORBRENA passes into your breast milk. Do not breastfeed during treatment with LORBRENA and for 7 days after the final dose. Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.

Do not take LORBRENA if you take certain other medicines called strong CYP3A inducers. Ask your healthcare provider for a list of these medicines if you are not sure.

The most common side effects of LORBRENA include:

swelling in your arms, legs, hands, and feet (edema)
numbness and tingling feeling in your joints or arms and legs (peripheral neuropathy)
difficulty thinking or confusion
difficulty breathing
tiredness (fatigue)
weight gain
pain in your joints
changes in mood, feeling sad or anxious
diarrhea

LORBRENA may cause decreased fertility in males. In males, this could affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.

These are not all of the possible side effects of LORBRENA. For more information, ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Indication

LORBRENA is a prescription medicine that is used to treat people with non-small cell lung cancer (NSCLC)

that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene, and
that has spread to other parts of the body, and
who have taken the medicine:
- alectinib, or ceritinib, or
- both crizotinib and at least 1 other medicine to treat NSCLC that is caused by the ALK gene, and
that is no longer responding to these treatments.

It is not known if LORBRENA is safe and effective in children.

The effectiveness of LORBRENA is based on a study that measured tumor response rate and duration of response. There is an ongoing study to find out how LORBRENA works over a longer period of time.

Please see Full Prescribing Information and Patient Information.

LORBRENA is a prescription medicine that is used to treat people with non-small cell lung cancer (NSCLC)

that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene, and
that has spread to other parts of the body, and
who have taken the medicine:
- alectinib, or ceritinib, or
- both crizotinib and at least 1 other medicine to treat NSCLC that is caused by the ALK gene, and
that is no longer responding to these treatments.

It is not known if LORBRENA is safe and effective in children.

The effectiveness of LORBRENA is based on a study that measured tumor response rate and duration of response. There is an ongoing study to find out how LORBRENA works over a longer period of time.

Making your support needs a priority. Together.

Co-Pay Assistance

Eligible, commercially insured patients may pay as little as $0 per month for LORBRENA.* There are no income requirements, forms, or faxing to enroll.

* Limits, terms, and conditions apply. Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico. Patients may receive up to $25,000 in savings annually. The offer will be accepted only at participating pharmacies. This offer is not health insurance. No membership fees apply. Pfizer reserves the right to rescind, revoke, or amend this offer without notice. For full terms and conditions, please see PfizerOncologyTogether.com/terms. For any questions, please call 1-877-744-5675, visit PfizerOncologyTogether.com/terms or write: Pfizer Oncology Together Co-Pay Savings Program, 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560.

Personalized Support

When you enroll in Pfizer Oncology Together, we'll connect you with a dedicated Care Champion who can offer you resources to help with some of your daily challenges.

Find Out More

Sign Up For LORBRENA^® Support

Use this form to request future resources, register for the $0 Co-Pay Savings Card,* or all of the above.

We are committed to providing support and resources designed for people taking LORBRENA (lorlatinib). If you are a patient, you also have the option to register for the $0 Co-Pay Savings Card.* Choose the support you’d like to receive by completing the form below.

All fields are required unless marked optional.

By filling out this form, you acknowledge you are age 18 or older.

I am a: *

Patient

Caregiver

Please tell us the support you’d like to register for (select all that apply). *

Future Resources

$0 Co-Pay Savings Card*

Email *

First Name *

Last Name *

Address *

Address 2

City *

State *

Zip *

Please verify the following to receive a $0 Co-Pay Savings Card:^*

I am age 18 or older.
I currently live in the United States or its territories.
I do not purchase my prescription medication through a federal or state prescription drug program such as Medicare or Medicaid.
I agree with the Terms and Conditions.

co-pay requirement check box

I meet the defined requirements.

Privacy Statement

Pfizer understands your personal and health information is private. The information you provide will only be used by Pfizer and companies working with Pfizer to send you materials and other helpful information and updates on LORBRENA, as well as related treatments, products, offers, and services.

* Limits, terms, and conditions apply. Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico. Patients may receive up to $25,000 in savings annually. The offer will be accepted only at participating pharmacies. This offer is not health insurance. No membership fees apply. Pfizer reserves the right to rescind, revoke, or amend this offer without notice. For full Terms and Conditions, please see PfizerOncologyTogether.com/terms. For any questions, please call 1-877-744-5675, visit PfizerOncologyTogether.com/terms or write: Pfizer Oncology Together Co-Pay Savings Program, 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560.

By checking

By checking this box, I also agree that Pfizer or companies working with Pfizer may send me materials about other health conditions, use my information to develop or improve products and services, or contact me in the future about health-related topics.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Website URL

Indication

Making your support needs a priority. Together.

Co-Pay Assistance

Personalized Support

Sign Up For LORBRENA® Support

You are now leaving LORBRENA.com.

You are now leaving LORBRENA.com.

Pfizer Oncology Together Co-Pay Savings Program

Terms and Conditions

Registration Complete

YOU’RE ALL SET!

Registration Complete

YOU’RE ALL SET!

Registration Complete

YOU’RE ALL SET!

Indication

Important Safety Information and Indication

Important Safety Information and Indication

Indication

Scroll for Important Safety Information and indication

Important Safety Information and Indication

Indication

Sign Up For LORBRENA^® Support